ZYME News and Press, Zymeworks Inc.

2026-04-01 06:17:21 ET More on Zymeworks Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript Zymeworks Inc. 2025 Q4 - Results - Earnings Call Presentation Zymeworks outlines $1.5B milestone po...

VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin ...

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) Ongoing Phase 1 clinical trial of ZW191 enrolling patients with adva...

VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the company’s partne...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR ⍺ )-targeting antibody-drug conjugate (ADC) New ADC candidates, including ZW437 and ZW418, demon...

2026-03-04 10:45:05 ET Thesis Read the full article on Seeking Alpha For further details see: Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

2026-03-02 21:19:18 ET More on Zymeworks Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript Zymeworks Inc. 2025 Q4 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Zymeworks...

2026-03-02 21:17:47 ET Zymeworks Inc. (ZYME) Q4 2025 Earnings Call March 2, 2026 8:30 AM EST Company Participants Shrinal Inamdar - VP of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO, Acting CFO & President Bijal Desai - Senior Vice Preside...

2026-03-02 10:37:35 ET Image source: The Motley Fool. Monday, March 2, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zy...